drugset

drugset / Trial / NCT03983018

Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)

NCT03983018 ↗

Phase 2 Completed 9 enrolled Region Örebro County Örebro University, Sweden · collab

NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant schizophrenia spectrum disorder in an open trial.

Timeline

Start: 2019-08-07
Primary completion: 2022-03-31
Completion: 2022-03-31

Publications

Results Bejerot S, Sigra Stein S, Welin E, Eklund D, Hylen U, Humble MB. Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: Two open-label pilot studies on treatment-resistant patients. J Psychiatr Res. 2023 Feb;158:319-329. doi: 10.1016/j.jpsychires.2022.12.003. Epub 2022 Dec 20.
Results Thunberg P, Fresnais D, Hamilton P, Bejerot S, Humble MB. Immunomodulatory treatment may change functional and structural brain imaging in severe mental disorders. Brain Behav Immun Health. 2024 Sep 16;41:100864. doi: 10.1016/j.bbih.2024.100864. eCollection 2024 Nov.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	1000 mg	Other

Indications